Korsana Biosciences, Inc. (KRSA) News
Follow Korsana Biosciences, Inc. (KRSA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Korsana Biosciences Reports 3Q Loss of $46.4M
EARNINGS | Nov 05, 2026, 12:15 PM UTC
M
Korsana Biosciences Reports Third-Quarter 2026 Results and Corporate Update
Korsana Biosciences says it completed a merger with Cyclerion Therapeutics alongside a $380 million private placement. The body is truncated after “Phase 1 h.”
EQUITY | Nov 05, 2026, 12:04 PM UTC
L
Korsana Biosciences Price Target Announced at $70.00/Share by Guggenheim
Ratings actions from Benzinga: GMT) Korsana Biosciences Initiated at Buy by GuggenheimRatings actions from Benzinga
NEWS | Sep 28, 2026, 12:35 PM UTC
L
Guggenheim initiates coverage of Korsana Biosciences with Buy rating, $70 price target
Guggenheim initiated coverage on Korsana Biosciences's stock with a rating of Buy and a price target of $70.00.The price target implies an upside of 125.8% from the Sep 25 close of $31.Key takeaways from the analyst note
EQUITY | Sep 28, 2026, 12:25 PM UTC
L
News On Cyclerion Therapeutics Inc. (CYCN) Now Under KRSA
News On Cyclerion Therapeutics Inc. (CYCN) Now Under KRSA
EQUITY | Sep 09, 2026, 09:08 PM UTC
M
KRSA completes merger closing with Cyclerion; $380M private placement
Korsana Biosciences (KRSA) completed the closing of its merger with Cyclerion Therapeutics and the previously announced private placement of $380 million.
MNA | Sep 08, 2026, 08:05 PM UTC